InVivo Therapeutics Stock (NASDAQ:NVIV)
Previous Close
$0.49
52W Range
$0.22 - $2.40
50D Avg
$0.70
200D Avg
$1.05
Market Cap
$995.92K
Avg Vol (3M)
$3.77M
Beta
0.66
Div Yield
-
NVIV Company Profile
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
NVIV Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SNTI | Senti Biosciences, Inc. |
| NTRB | Nutriband Inc. |
| NXTC | NextCure, Inc. |
| BWV | Onconetix, Inc. |
| SABS | SAB Biotherapeutics, Inc. |
| KPRX | Kiora Pharmaceuticals, Inc. |
| LGVN | Longeveron Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| REVB | Revelation Biosciences, Inc. |
| SPRO | Spero Therapeutics, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| HILS | Tharimmune, Inc. |
| HCWB | HCW Biologics Inc. |
| VRAX | Virax Biolabs Group Limited |
| ASMB | Assembly Biosciences, Inc. |
| RNXT | RenovoRx, Inc. |
| RZLT | Rezolute, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| MOLN | Molecular Partners AG |
| NLTX | Neurogene Inc. |
| ELYM | Eliem Therapeutics, Inc. |